How Titan Biotech Turned ₹1 Lakh into ₹50 Lakh — A Value Investing Case Study

Infographic Titled the Piotroski F score with a 6 year Bar Chart of Financial Scores fy20fy25 Showing Values from 11 to 32 and a Green Fy25 Bar
The Piotroski F-Score: A 9-Point Checklist That Separates Multibaggers from Value Traps
March 15, 2026
Hero Header with the Title economic Moats and Green Subtitle on a Dark Blue Background a Two by two Color Block Grid Labeled Trader gray Compunder green Drift light Gray Speculator orange Footer Credit Text
Economic Moats: How to Find Companies That Competitors Simply Cannot Destroy
March 16, 2026
Hero Title How Titan Biotech Turned ₹1 Lakh with a Subtitle About Audited Fy25 Numbers and Shares Growth illustrative Article Header

#image_title

VALUE INVESTING · BLOG

How Titan Biotech Turned ₹1 Lakh into ₹50 Lakh — A Value Investing Case Study

← ALL ARTICLES
Mbcover How Titan Biotech Turned E28 - Manish Goel Portfolio Management Service
📅 Published
March 15, 2026 (Sunday)

From Penny Stock to Multibagger — A 50x Journey

Imagine investing ₹1 Lakh in a single stock and watching it grow to ₹50 Lakh. That’s exactly what happened with Titan Biotech Ltd (BSE: 524717).

Stock Price Journey

  • 2016: ~₹8 per share
  • March 2026: ~₹400 per share
  • Total Return: Approximately 50x (5,000%)

If you had invested just ₹1 Lakh in 2016, it would be worth approximately ₹50 Lakh today.

The Business Behind the Returns

Titan Biotech is not just a stock story — it’s a business transformation story. The company manufactures biological and pharmaceutical products including culture media, agar, peptones, and yeast extracts used in diagnostics and research.

5-year trajectory
Figure 1. 5-year trajectory — Audited FY20-FY25 (Titan-illustrative)

Revenue Growth

  • FY2015 Revenue: ₹46 Crore
  • FY2025 Revenue: ₹156 Crore
  • CAGR: ~15% over 10 years
  • Latest EPS (Q2 FY2026): ₹8.30 per share

5 Reasons Titan Biotech Became a Multibagger

  1. Consistent Revenue Growth — 15% CAGR over a decade shows business durability
  2. Niche Market Leader — Dominates biological products segment with limited competition
  3. Expanding Margins — Operating margins improved as scale increased
  4. Low Debt — Conservative balance sheet with minimal leverage
  5. Under-Researched Stock — No major analyst coverage meant the stock was available at deep value

The 7-Step Value Investing Framework

These are the exact principles I use to identify multibagger opportunities:

  1. Step 1: Look for businesses with consistent revenue growth (minimum 10% CAGR)
  2. Step 2: Check for expanding profit margins over 3-5 years
  3. Step 3: Ensure low debt-to-equity ratio (below 0.5 preferred)
  4. Step 4: Look for high Return on Equity (above 15%)
  5. Step 5: Verify promoter holding is stable or increasing
  6. Step 6: Buy when valuation is reasonable (P/E below industry average)
  7. Step 7: Hold with patience — multibaggers take 5-10 years to fully compound

Key Takeaway

The biggest mistake investors make is selling too early. Titan Biotech tested patience many times — sideways movement, temporary dips, market crashes. But investors who held through the noise were rewarded with life-changing returns.

Value investing is not about finding the next hot tip. It’s about finding solid businesses at reasonable prices and having the patience to let compounding work its magic.

Disclaimer: This content is published by Manish Goel, SEBI Registered Research Analyst (INH100004775). This is for educational purposes only and should not be considered investment advice. Investments in securities are subject to market risks. Please consult your financial advisor before making investment decisions.

FY25 decomposition
Figure 2. FY25 decomposition — Where the ratio comes from

— Manish Goel
Founder, Manish Goel
SEBI Registered Research Analyst: INH100004775
Website: manishgoelpms.com | www.manishgoelpms.com

📢 Join Our Telegram Channel

Get daily value investing lessons, stock analysis & Titan Biotech updates — delivered straight to your phone!

✈️ Join @longtermequityy on Telegram

🔔 Free • No spam • Value investing insights daily

MG Manish Goel Portfolio Management Service
SEBI Registered Research Analyst · Registration No. INH100004775 · Principal Officer: Manish Goel · 2209, Sector 63, Chandigarh — 160047, India
Investments are subject to market risks. Past performance is not indicative of future returns. Please read all documents carefully.
© 2026 Manish Goel Portfolio Management Service. All rights reserved. · Privacy · Disclaimer
author avatar
Manish Goel
Manish Goel is a Chartered Accountant, SEBI Registered Research Analyst, and founder of Manish Goel PMS. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.
+91-7380122211